The Federal Trade Commission is challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic.
FILE - The injectable drug Ozempic is displayed, July 1, 2023, in Houston. Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
“By filing bogus patent listings, pharma companies block competition and inflate the cost of prescription drugs, forcing Americans to pay sky-high prices for medicines they rely on,” said FTC Chair Lina Khan, in a statement. Companies receiving the letters have 30 days to withdraw or update their patent listings, or “certify under penalty of perjury” that they are legitimate, according to the FTC. The patents are registered with the Food and Drug Administration, which reviews and approves new drugs.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Federal Trade Commission rules most noncompetes to be unlawful soonAndrew Christiansen is KGUN 9's Catalina Foothills reporter. Send your story ideas to Andrew at andrew.christiansenkgun9.com.
Read more »
Federal Trade Commission Bans Noncompete Agreements, Urges More Protections for Healthcare WorkersThe FTC's decision to ban noncompete agreements could make it easier for doctors and other healthcare workers to switch jobs. But business groups say they will sue to block it.
Read more »
Federal trade commission sues to block $8.5 billion merger of Coach and Michael KorsThe agency said that the deal would eliminate direct head-to-head competition between the fashion companies’ brands like Coach and Michael Kors in the…
Read more »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd.
Read more »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd.
Read more »
Federal Trade Commission sues to block Tapestry's $8.5B acquisition of CapriThe Federal Trade Commission sued to block Tapestry, Inc.’s $8.5 billion acquisition of Capri Holdings Ltd., saying that the deal would eliminate direct head-to-head competition between the fashion companies’ brands like Coach and Michael Kors in the so-called affordable luxury handbag arena.
Read more »